Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 944-482-9 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
No experimental toxico-kinetic data are available for assessing adsorption, distribution, metabolisation and excretion of the substance. Based on effects seen in the human health toxicity studies and physico-chemical parameters Galbascone is expected to be readily absorbed via the oral and inhalation route and somewhat lower via the dermal route. Using the precautionary principle for route to route extrapolation the final absorption percentages derived are: 50% oral absorption, 50% dermal absorption and 100% inhalation absorption.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
- Absorption rate - oral (%):
- 50
- Absorption rate - dermal (%):
- 50
- Absorption rate - inhalation (%):
- 100
Additional information
- Reduction of the ketone group to a secondary alcohol
- Hydroxylation/oxygenation of the cyclohexene ring
- Oxidation of the angular methyl groups -
- Reduction of the double bond in the exocyclic alkenyl side chain or cyclic portion of the molecule to form dihydro derivatives
- Epoxidation of isolated (non-conjugated) double bounds of exocyclic alkyl chains and subsequent reaction with epoxide hydrolases or glutathione transferase
- Conjugation of the hydroxylated metabolites
- Conjugation of epoxide metabolites.
Introduction
The test material Galbascone (Cas no 56973-85-4) is a pent-4-en-1-one attached to the double bond of a 5,5-dimethyl-1-cyclohexenyl resulting in an alpha,beta unsaturated ketone. It is a liquid with a molecular weight of 192, water solubility (WS) of 88.9 mg/L and a log Kow of 4.5 that does not preclude absorption. The test material has no hydrolysable groups. The substance has a low volatility of 1.14 Pa.
Absorption
Oral:The results of the repeat dose oral toxicity of Galbascone show that the substance is being absorbed by the gastro-intestinal tract following oral administration, because effects were seen on body weight, liver, kidney and urinary bladder. The relatively low molecular weight and the moderate octanol/water partition coefficient (Log Kow 4.5) and water solubility (88.9 mg/L) would favour absorption through the gut. According to Martinez and Amidon (2002) the optimal log Kow for oral absorption falls within a range of 2-7. This shows that Galbasconeis likely to be absorbed orally and therefore the oral absorption is expected to be > 50%.
Skin: Based on the physico-chemical characteristics of the substance, being a liquid, its molecular weight (192), log Kow (4.5) and water solubility (88.9 mg/L), indicate that (some) dermal absorption is likely to occur. The optimal MW and log Kow for dermal absorption is < 100 and in the range of -1 to +4, respectively (ECHA guidance, 7.12, Table R.7.12-3). According to the ECHA guidance, a default value of 100% skin absorption is generally used unless molecular mass is above 500 and log P is outside the range -1 to +4, in which case a value of 10% skin absorption is chosen. Based on the physico-chemical properties of Galbascone (the log Kow > 4), the skin absorption is expected to be <= 50%.
Lungs: Absorption via the lungs is also indicated based on these physico-chemical properties. Though the inhalation exposure route is thought minor, because of its low volatility (1.14 Pa), the octanol/water partition coefficient (4.5), indicates that inhalation absorption is possible.
Distribution
The moderate water solubility of the test substance would limit distribution in the body via the water channels. The log Kow would suggest that the substance would pass through the biological cell membrane. Due to the expected metabolisation the substance as such would not accumulate in the body fat.
Metabolism
There are no actual data on the metabolisation of Galbascone. Possible primary and secondary steps of metabolism are (Belsito et al, 2013):
-primary metabolism
-secondary metabolism
Excretion
Because of the moderate water solubility and the relatively low molecular weight, Galbascone and its metabolites are expected to be excreted mainly via urine, and possibly also via the bile. Any unabsorbed substance will be excreted via the faeces.
Discussion
Galbascone is expected to be readily absorbed, orally and via inhalation, based on the human toxicological information and physico-chemical parameters. The substance also is expected to be absorbed dermally based on the physico-chemical properties. The MW is below the limit value and the log Kow is higher than the favourable range for dermal absorption and therefore significant absorption is likely.
The IGHRC (2006) document of the HSE - also mentioned in the ECHA guidance Chapter 8 - will be followed to derive the final absorption values for the risk characterisation.
Oral to dermal extrapolation
There are adequate data via the oral route and the critical toxic effect is related to systemic effects and therefore route to route extrapolation is applicable. The toxicity of the substance will be due to the parent compound but also to its metabolites. The overriding principle will be to avoid situations where the extrapolation of data would underestimate toxicity resulting from human exposure to a chemical by the route to route extrapolation. Some first pass effect via the liver may also occur. The toxicity of the dermal route will not be underestimated because absorption will be slower and the compound will also pass the liver. Therefore it will be assumed that the oral absorption will equal dermal absorption. Forrisk assessment purposes the oral absorption will be considered 50% (though likely to be higher) and the dermal absorption will be considered also 50% (though likely to be lower).
Oral to inhalation extrapolation
Though Galbascone is not a volatile liquid inhalation exposure will be considered. Galbascone is not a corrosive for skin and eye and the systemic effect will overrule the effects at the site of contact. In the absence of bioavailability data it is most precautionary that 100% of the inhaled vapour is bioavailable. For inhalation absorption 100% will be used for route to route extrapolation, because this will be precautionary for the inhalation route.
Conclusion
Galbascone is expected to be readily absorbed via the oral and inhalation route and somewhat lower via the dermal route based on toxicity and physico-chemical data. Using the precautionary principle for route to route extrapolation the final absorption percentages derived are: 50% oral absorption, 50% dermal absorption and 100% inhalation absorption.Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.